Abstract
Objective
To examine the imaging characteristics of intramuscular myxomas (IM) and myxoid liposarcomas (MLS) on 18F-FDG PET/CT and MRI.
Materials and methods
With IRB approval, our institutional imaging database was searched for pathologically proven IM and MLS evaluated by 18F-FDG PET/CT and MRI. PET/CT and MRI imaging characteristics were recorded and correlated with pathologic diagnosis.
Results
We found eight patients (2 M, 6 F) with IM (mean age 65.6 ± 10.4 years) and 16 patients (7 F, 9 M) with MLS (mean age 42.8 ± 16.3 years). MRI was available in 7/8 IM and 15/16 MLS patients. There was no significant difference between the two groups in SUVmax (IM 2.7 ± 0.8, MLS 3.0 ± 1.0; p = 0.35), SUVmean (1.7 ± 0.4, 1.5 ± 0.5; p = 0.40), total lesion glycolysis (101.8 ± 127.3, 2420.2 ± 4003.3 cm3*g/ml; p = 0.12), metabolic tumor volume (62.3 ± 71.1, 1742.9 ± 3308.0 cm3; p = 0.17) or CT attenuation (p = 0.70). MLS occurred in younger patients (p = 0.0015), were larger (16.4 ± 8.2 vs. 5.6 ± 2.5 cm; p = 0.0015), more often T1 hyperintense (p = 0.03), with nodular enhancement (p = 0.006), and macroscopic fat on CT (p = 0.0013) and MRI (p = < 0.001) compared to myxomas.
Conclusions
IM and MLS most commonly demonstrate low-grade FDG activity and overlapping metabolic measures on PET/CT. MRI is useful in differentiation, but MLS can present without macroscopic fat on MRI, underscoring the importance of radiologic-pathologic correlation for accurate diagnosis.
Similar content being viewed by others
References
Baheti AD, Tirumani SH, Rosenthal MH, Howard SA, Shinagare AB, Ramaiya NH, et al. Myxoid soft-tissue neoplasms: comprehensive update of the taxonomy and MRI features. AJR Am J Roentgenol. 2015;204(2):374–85.
Petscavage-Thomas JM, Walker EA, Logie CI, Clarke LE, Duryea DM, Murphey MD. Soft-tissue myxomatous lesions: review of salient imaging features with pathologic comparison. Radiographics: a review publication of the Radiological Society of North America, Inc. 2014;34(4):964–80.
Murphey MD, McRae GA, Fanburg-Smith JC, Temple HT, Levine AM, Aboulafia AJ. Imaging of soft-tissue myxoma with emphasis on CT and MR and comparison of radiologic and pathologic findings. Radiology. 2002;225(1):215–24.
Gimber LH, Montgomery EA, Morris CD, Krupinski EA, Fayad LM. MRI characteristics associated with high-grade myxoid liposarcoma. Clin Radiol. 2017;72(7):613.e611–6.
Crombe A, Alberti N, Stoeckle E, Brouste V, Buy X, Coindre JM, et al. Soft tissue masses with myxoid stroma: can conventional magnetic resonance imaging differentiate benign from malignant tumors? Eur J Radiol. 2016;85(10):1875–82.
Peterson KK, Renfrew DL, Feddersen RM, Buckwalter JA, el-Khoury GY. Magnetic resonance imaging of myxoid containing tumors. Skelet Radiol. 1991;20(4):245–50.
Jelinek JS, Kransdorf MJ, Shmookler BM, Aboulafia AJ, Malawer MM. Liposarcoma of the extremities: MR and CT findings in the histologic subtypes. Radiology. 1993;186(2):455–9.
Sung MS, Kang HS, Suh JS, Lee JH, Park JM, Kim JY, et al. Myxoid liposarcoma: appearance at MR imaging with histologic correlation. Radiographics. 2000;20(4):1007–19.
Fisher SM, Joodi R, Madhuranthakam AJ, Öz OK, Sharma R, Chhabra A. Current utilities of imaging in grading musculoskeletal soft tissue sarcomas. Eur J Radiol. 2016;85(7):1336–44.
Nielsen GP, O'Connell JX, Rosenberg AE. Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Am J Surg Pathol. 1998;22(10):1222–7.
Ergul N, Aydin M. FDG PET/CT findings in rare sarcomas. Rev Esp Med Nucl Imagen Mol. 2013;32(5):324–7.
Munksgaard PS, Salkus G, Iyer VV, Fisker RV. Mazabraud's syndrome: case report and literature review. Acta Radiol Short Rep. 2013;2(4):2047981613492532.
Singnurkar A, Phancao JP, Chatha DS, Stern J. The appearance of Mazabraud's syndrome on 18F-FDG PET/CT. Skelet Radiol. 2007;36(11):1085–9.
Yamashita H, Endo K, Takeda C, Teshima R, Osaki M, Yoshida H. Intramuscular myxoma of the buttock mimicking low-grade fibromyxoid sarcoma: diagnostic usefulness of MUC4 expression. Skelet Radiol. 2013;42(10):1475–9.
Nishio J, Naito M. FDG PET/CT and MR imaging of intramuscular myxoma in the gluteus maximus. World J Surg Oncol. 2012;10:132.
Ho L, Wassef H, Henderson R, Seto J. F-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in left thigh intramuscular myxoma. Clin Nucl Med. 2009;34(4):224–5.
Sridhar P, Mercier G, Tan J, Truong MT, Daly B, Subramaniam RM. FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. Am J Roentgenol. 2014;202(5):1114–9.
Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82(3):1164–71.
Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010;51(8):1174–81.
Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006;33(11):1290–5.
Suzuki R, Watanabe H, Yanagawa T, Sato J, Shinozaki T, Suzuki H, et al. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma. Ann Nucl Med. 2005;19(8):661–70.
Nose H, Otsuka H, Otomi Y, Terazawa K, Takao S, Iwamoto S, et al. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions. J Med Investig. 2013;60(3.4):184–90.
Schwab JH, Healey JH. FDG-PET lacks sufficient sensitivity to detect myxoid liposarcoma spinal metastases detected by MRI. Sarcoma. 2007;2007:36785.
Estourgie SH, Nielsen GP, Ott MJ. Metastatic patterns of extremity myxoid liposarcoma and their outcome. J Surg Oncol. 2002;80(2):89–93.
Asano N, Susa M, Hosaka S, Nakayama R, Kobayashi E, Takeuchi K, et al. Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experience. Sarcoma. 2012;2012:345161.
Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer. 2007;110(8):1815–22.
Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA. Metastatic myxoid liposarcomas: imaging and histopathologic findings. Skelet Radiol. 2008;37(3):251–8.
Tateishi U, Hasegawa T, Beppu Y, Kawai A, Satake M, Moriyama N. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol. 2004;182(3):725–31.
Song Y, Yoon YC, Chong Y, Seo SW, Choi YL, Sohn I, et al. Diagnostic performance of conventional MRI parameters and apparent diffusion coefficient values in differentiating between benign and malignant soft-tissue tumours. Clin Radiol. 2017;72(8):691.e691–10.
Ahlawat S, Fayad LM. Diffusion weighted imaging demystified: the technique and potential clinical applications for soft tissue imaging. Skeletal Radiol. 2018;47(3):313–28.
Sujlana P, Skrok J, Fayad LM. Review of dynamic contrast-enhanced MRI: Technical aspects and applications in the musculoskeletal system. J Magn Reson Imaging. 2018;47(4):875–90.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Disclosures
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Lunn, B.W., Littrell, L.A., Wenger, D.E. et al. 18F-FDG PET/CT and MRI features of myxoid liposarcomas and intramuscular myxomas. Skeletal Radiol 47, 1641–1650 (2018). https://doi.org/10.1007/s00256-018-3000-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00256-018-3000-y